For several years my colleagues, J. Bellanti and M. Artenstein, and I have studied the occurrence of specific antibodies in secretions of the respiratory tract, and have attempted to evaluate their biological significance (2, 3, 3a) . This interest stemmed from the need for a simple biological marker to identify persons most likely to resist overt respiratory infection with any of several viruses. As with respiratory tularemia, the presence or titer of humoral antibodies to respiratory viruses is not synonymous with resistance to clinical disease upon infection. When these investigations were begun, it was our purpose to identify such markers. We (2) twice daily for 3 days before and for 5 days after challenge, and at weekly intervals thereafter for 6 weeks. Daily collections of nasal washings from each volunteer were pooled, concentrated approximately 10-fold by lyophilization after dialysis against distilled water, and studied for hemagglutinating antibody to polysaccharide prepared from the SCHU-S4 strain. Antibody determinations were made by the method of Alexander (1) modified for microtiter technique. Hemagglutinating antibody was measured because it is more readily detected in higher titers than are cell agglutinins (4).
Nasal antibody was indeed detected 3 months after percutaneous immunization, prior to challenge by aerosol infection ( Table 1) . Titers of nasal antibody ranged from 1:2 to 1:32 per 0.05 ml of concentrated nasal washing, and, for the most part, were significantly lower than those observed simultaneously in serum. There was no clear correlation between titers of antibody in serum with those found in secretions (Table 2) , although too few individuals were studied to make absolute comparisons. However meager, the hemagglutinin differed between serum and secretions. The majority of antibody activity in serum was associated primarily with the yM immunoglobulins, whereas nasal antibody was found primarily in eluates containing yA immunoglobulins, and this pattern was the same after either percutaneous or aerosol infection. These observations show that there is no significant difference in the nature of local or humoral distribution of hemagglutinin to F. tularensis between persons infected percutaneously or by the respiratory route. If this antibody in any way reflects resistance to overt infection (and there certainly are reasons to question this assumption), it may be properly concluded that such differences as might be effected by varying the route of vaccine administration would be only chronological. Hornick and Eiglesbach showed that the humoral antibody response following aerosol immunization is more rapid than the response to percutaneous vaccination (5) . Whether local antibody appears in the respiratory tract less rapidly after percutaneous immunization is, of course, unknown, but is readily subjected to test in percutaneously immunized volunteers.
Even if respiratory antibody appears more RESPIRATORY ANTIBODY TO F. TULARENSIS promptly after aerosol immunization, there are few circumstances which demand this extraordinarily prompt immune response. Further, it is clear that, despite the presence of respiratory antibody, the immunity induced by any method of immunization can be overwhelmed by challenge with more than 10,000 virulent cells. Finally, Hornick's experience shows that administration of LVS vaccine by aerosol is not without risk of reaction (5) . Indeed, to obtain optimal protection for up to 6 months, it appears necessary to administer over 106 to 108 viable vaccine cells. Approximately 80% of those receiving these doses of vaccine had, as a reaction, overt but mild respiratory tularemia. This appears to be a greater price for an additional short interval of immunity than we would be willing to pay.
Finally, it is clear that this experimentation is seriously limited by the lack of a good reproducible marker for immunity (resistance to overt infection). It is not now possible to evaluate local antibody as a marker for immunity to F. tularensis, although in one other respiratory infection there appears to be a good correlation between presence of respiratory antibody and resistance to infection. Experiments with parainfluenza virus type 1 in man show that persons with nasal neutralizing antibody are more resistant to challenge infection than are those without, irrespective of their humoral antibody status (Smith et al., New Engl. J. Med. in press). Thus, recent experimental evidence strongly suggests that detailed analysis of respiratory secretions may well provide better markers for immunity to respiratory infections. This experimental approach is not technically difficult today, and should be extended further into the problem at hand.
